1Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? [J]. Clin Infect Dis,2002,34(5) :634-640.
2Hsueh PR, Teng LJ, Chen CY, et al. Pandrug-resistant Acinetobatter baumannii causing nosocomial infections in a university hospital, Taiwan[J]. Emerg Infect Dis,2002, 8(8) :827-832.
3Evans ME, Feola DJ, Rapp RP. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria[J]. Ann Pharmacother, 1999,33(9):960-967.
4Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004) [J]. Clin Microbiol Infect, 2006,12(4) :315-321.
5Falagas ME, Kasiakou SK,Tsiodras S, et al. The use of intravenous and aerosolized polymyxins for the treatment of in fections in critically ill patients., a review of the recent litera ture[J]. Clin Med Res, 2006, 4(2) : 138-146.
6Gough M, Hancock RE, Kelly NM. Antiendotoxin activity of cationic peptide antimicrobial agents [J]. Infect Immun, 1996, 64(12) :4922-4927.
7Gales AC, Reis AO,Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines[J]. J Clin Microbiol, 20010 39(1) : 183-190.
8Li J, Nation RL, Milne RW, et al. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria[J]. lnt J Antimicrob Agents, 2005, 25 (1):11-25.
9Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 2005,49(12):3624-3630.
10Markou N, Apostolakos H, Koumoudiou C, et al. Intravenous eolistin in the treatment of sepsis from multiresistant Gram-negative baeilli in critically ill patients[J]. Crit Care, 2003, 7(5) :R78-R83.
